Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational

References

• Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-9
   PubMed Web of Science ®Google Scholar
• Manuel DG, Leung M, Nguyen K, et al. Burden of cardiovascular disease in Canada. Can J Cardiol 2003;19:997-1004
   PubMed Web of Science ®Google Scholar
• Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38-48
   PubMed Web of Science ®Google Scholar
• Tsuyuki RT, Shibata MC, Nilsson C, et al. Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol 2003;19:436-8
   PubMed Web of Science ®Google Scholar
• Bennett SJ. Perceived threats of individuals recovering from myocardial infarction. Heart Lung 1992;21:322-6
   PubMed Web of Science ®Google Scholar
• Conn VS, Taylor SG, Wiman P. Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction. Issues Ment Health Nurs 1991;12:321-31
   PubMedGoogle Scholar
• Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996;58:99-110
   PubMed Web of Science ®Google Scholar
• Miller PJ, Wikoff R. Spouses’ psychosocial problems, resources, and marital functioning postmyocardial infarction. Prog Cardiovasc Nurs 1989;4:71-6
   PubMedGoogle Scholar
• Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003;163:333-9
   PubMed Web of Science ®Google Scholar
• Johansen H. Living with heart disease: the working-age population. Health Rep 1999;10:33-45
   PubMedGoogle Scholar
• Economic burden of illness in Canada, 1998. Services Canada, 2002. Available at: http://www.phac-aspc.gc.ca/publicat/ebic-femc98/. Accessed on 14 November 2008
   Google Scholar
• Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51
   PubMed Web of Science ®Google Scholar
• Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-82
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27
   PubMed Web of Science ®Google Scholar
• Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
   PubMed Web of Science ®Google Scholar
• Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study – Observational (CALIPSO). Can J Cardiol 2005;21:1187-93
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
   PubMed Web of Science ®Google Scholar
• Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2006;191:135-46
   PubMed Web of Science ®Google Scholar
• Clark LT, Maki KC, Galant R, et al. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med 2006;21:320-6
   Google Scholar
• Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708
   PubMed Web of Science ®Google Scholar
• Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45
   PubMed Web of Science ®Google Scholar
• Lachaine J, Rinfret S, Merikle EP, et al. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l’Assurance Maladie du Quebec data. Am Heart J 2006;152:164-9
   PubMed Web of Science ®Google Scholar
• Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar